Gil C / Shutterstock.com
The English High Court has ruled in favour of Merck Sharp & Dohme (MSD) in a patent battle against Shionogi, over MSD's product Isentress (raltegravir).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck Sharp & Dohme, Shionogi, Isentress, Tivicay, Anti-HIV, patent, patent infringement